Axis Direct is bullish on Apollo Hospitals has recommended buy rating on the stock with a target price of Rs 1336 in its research report dated February 22, 2018.
Axis Direct's research report on Apollo Hospitals
Apollo Hospitals' Q3FY18 revenue (adjusted for GST) increased 16% YoY to Rs 19 bn, while EBITDA increased 14% YoY to Rs 2.2 bn. Results could have been better had it not been for (1) Regulatory caps on stent & knee implant prices, (2) Rs 105 mn loss from Navi Mumbai facility; (3) Rs 70 mn guarantee money paid to doctors; & (4) Adverse GST rate revisions on input service.
Outlook
PAT of Apollo Hospitals over the past 5 years has remained flat on account of higher investments in setting up new hospitals and clinics. However, over FY17-20, Apollo is adding mere 265 beds and we expect beds which were commissioned over the past 3 years to show margin expansion.For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Read More
